Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China have?
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China has 259 citations in the OpenAlex counts ScholarIQ stores.
When was Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China published?
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China has 2017 year in the ScholarIQ index.
What is the open-access status of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China has gold oa status in the ScholarIQ index.
What is the DOI of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?
The DOI for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is on the source record.
What is the PMID of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?
The PMID for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is on the source record.
What is the OpenAlex record for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China?
The OpenAlex for Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China is on the source record.